Irish Jian 4
4 · Metagenomi Therapeutics, Inc. · Filed Apr 3, 2026
Research Summary
AI-generated summary of this filing
Metagenomi (MGX) CEO Jian Irish Receives RSU/Option Awards
What Happened Jian Irish, President and Chief Executive Officer of Metagenomi Therapeutics, was granted awards on April 1, 2026: 46,000 restricted stock units (RSUs) and 276,000 derivative awards (reported as a derivative grant). Both grants show an acquisition price of $0.00 (typical for compensation grants). No cash purchase or sale occurred.
Key Details
- Transaction date: April 1, 2026; Form 4 filed April 3, 2026 (file appears timely).
- Grants: 46,000 RSUs (F1) and 276,000 derivative awards (reported as derivative; F4 describes option-like vesting).
- Price: $0.00 per share (compensation award).
- Vesting (per footnotes):
- RSUs (F1): 25% vest on June 5, 2027; remaining 75% vest in 12 equal quarterly installments thereafter, subject to continued service.
- Derivative/option-style award (F4): 25% vest on April 1, 2027; remainder vests in 36 equal monthly installments, subject to continued service.
- Shares held in trusts (F2, F3) are noted; the reporting person disclaims beneficial ownership of those trusts' shares except to the extent of any pecuniary interest.
- Form does not specify total shares owned by the reporting person after these grants in this report.
Context These entries are grants of equity compensation (RSUs and a derivative/option-style award) and are routine for executives; they are not open-market purchases or sales. Vesting is time‑based and contingent on continued service, so the economic or voting rights typically only arise as portions vest. Trust-held shares noted in the filing are reported separately and do not necessarily indicate direct beneficial ownership by the insider.
Insider Transaction Report
- Award
Common Stock
[F1]2026-04-01+46,000→ 379,770 total - Award
Stock Option (Right to Buy)
[F4]2026-04-01+276,000→ 276,000 totalExercise: $1.34Exp: 2036-03-31→ Common Stock (276,000 underlying)
- 292,714(indirect: By Trust)
Common Stock
[F2] - 292,713(indirect: By Trust)
Common Stock
[F3]
Footnotes (4)
- [F1]These shares represent restricted stock units ("RSUs"). 25% of the RSUs shall vest on June 5, 2027, with the remainder vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date.
- [F2]Shares held by the Bruce Irish 2023 Irrevocable Trust FBO Jian Irish. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
- [F3]Shares held by the Jian Irish 2023 Irrevocable Trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
- [F4]25% of the shares subject to this option shall vest and become exercisable on April 1, 2027, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date.